Neuren Pharmaceuticals (ASX:NEU)
ASX announcement history & article coverage
Transparent by design.
Announcments by Neuren Pharmaceuticals (ASX:NEU) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Dividend/Distribution - NEU
Neuren Pharmaceuticals declares fully franked AUD 0.15 dividend for H1 2026
Investor presentation, 26 August 2026
Growing royalty anchors Neuren first ever dividend program
Neuren launches first dividend program backed by rising DAYBUE royalties and strong H1 2026 results
Half Yearly Report and Accounts
Neuren reports H1 2026 revenue growth, profit decline, and declares first interim dividend
European Commission grants marketing authorisation for DAYBU
European Commission approves DAYBU for Rett syndrome; Neuren to receive milestone payments
Neuren H1 2026 Financial Results Webinar on 26 August 2026
Neuren Pharmaceuticals schedules H1 2026 financial results webinar for 26 August 2026
Record Q2 DAYBUE net sales of US$125m, CY26 royalty upgraded
Neuren reports record Q2 DAYBUE sales and upgrades 2026 royalty guidance
Neuren highlights participation in PMSF Family Conference
DAYBU recommended for approval in the European Union
CHMP recommends EU approval for Neuren's DAYBU® to treat Rett syndrome
Application for quotation of securities - NEU